Regulatory and Commercial: AXS-07 for migraine, NDA resubmission 1H 2024; AXS-14 for fibromyalgia, NDA submission 4Q 2023 – 1Q 2024. Clinical Trial Readouts: Phase 3 SYMPHONY trial of AXS-12 in narcolepsy 4Q 2023; Phase 3 ADVANCE-2 trial of AXS-05 for Alzheimer’s disease agitation 1H 2024; Phase 3 FOCUS trial of solriamfetol in ADHD in adults 2H 2024. Clinical Trial Initiations: Phase 3 trial of solriamfetol for binge eating disorder 4Q 2023; Phase 3 trial of solriamfetol in shift work disorder 1Q 2024; Pivotal Phase 2/3 trial of AXS-05 for smoking cessation 4Q 2023 – 1Q 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- AXSM Upcoming Earnings Report: What to Expect?
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Axsome Therapeutics price target lowered to $190 from $200 at H.C. Wainwright
- Short Report: Bearishness on BioXcel at record high amid trial conduct review